Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients
Authors:
- 1 September 2006
- journal article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 65 (9) , 1233-1236
Abstract
Objective: To understand the use of tumour necrosis factor (TNF)α inhibitors in refractory dermatomyositis and polymyositis in an academic centre. Methods: A retrospective study of eight patients with dermatomyositis or polymyositis refractory to corticosteroids and immunosuppressives who were treated with TNF inhibitors between 1998 and 2004. Results: 8 patients with dermatomyositis or polymyositis who were treated with TNF inhibitors as adjunct treatment were identified. The mean (SD) duration of disease before initiation of TNF inhibitors was 8.5 (4.4) years. The patients failed to respond to treatment with corticosteroids (oral and intravenous); intravenous immunoglobulin and immunosuppressants (methotrexate, azathioprine, mucophenolate mofetil and leflunomide); 4.5 (1.4) immunosuppressants had been used before TNF treatment. Six patients were treated with etanercept alone, one with infliximab and one sequentially with both agents. Of the eight patients, six showed a favourable response with improved motor strength and decreased fatigue after 15.2 (6.5) months. Two of the patients did not respond after 4 (1.4) months and TNF inhibitors were discontinued. Responders showed a 54.4% (27.7%) decrease in serum concentration of creatine kinase, which was grossly abnormal (4463.5 (4036.4) U/l). Non-responders had similar reductions in creatine kinase concentration (56.1% (20.4%)), but their pre-treatment concentrations were in the normal range (118.5 (19.1) U/l). Conclusion: Anti-TNF agents may be useful in some patients with refractory dermatomyositis or polymyositis.Keywords
This publication has 15 references indexed in Scilit:
- International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathiesArthritis & Rheumatism, 2005
- Treatment of Dermatomyositis and Polymyositis with Anti-Tumor Necrosis Factor-α: Long-Term Follow-UpEuropean Neurology, 2004
- Treatment of myositis with etanercept (Enbrel®), a recombinant human soluble fusion protein of TNF-α type II receptor and IgG1Rheumatology, 2004
- Polymyositis and dermatomyositisThe Lancet, 2003
- Successful Treatment of Dermatomyositis and Polymyositis with Anti-Tumor-Necrosis-Factor-Alpha: Preliminary ObservationsEuropean Neurology, 2003
- Associations of Tumor Necrosis Factor α and HLA Polymorphisms with Adult Dermatomyositis: Implications for a Unique Pathogenesi1Journal of Investigative Dermatology, 2002
- Expression of tumor necrosis factor-α in muscles of polymyositisJournal of the Neurological Sciences, 1997
- Cytokine Expression Profile in Idiopathic Inflammatory MyopathiesJournal of Neuropathology & Experimental Neurology, 1996
- Analysis of cytokine expression in muscle in inflammatory myopathies, Duchenne dystrophy, and non-weak controlsJournal of Neuroimmunology, 1995
- Polymyositis and DermatomyositisNew England Journal of Medicine, 1975